Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Abstract

In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a <i>BRCA</i> mutation. (Funded by ARCAGY Research and others; PAOLA-1 ClinicalTrials.gov number, NCT02477644.).

Keywords

OlaparibBevacizumabOvarian cancerMedicineOncologyBRCA mutationMaintenance therapyInternal medicineCancerChemotherapyPoly ADP ribose polymeraseBiologyGenetics

Affiliated Institutions

Related Publications

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

Pui San Tan , Gilberto Lopes , Sanchalika Acharyya +2 more

Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefi...

2015 European Journal of Cancer 17 citations

Publication Info

Year: 2019
Type: article
Volume: 381
Issue: 25
Pages: 2416-2428
Citations: 1845
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1845

OpenAlex

Cite This

APA Style

                            
                                
                                    Isabelle Ray‐Coquard, 
                                
                                    Patricia Pautier, 
                                
                                    Sandro Pignata
                                
                                et al.
                            
                            (2019). 
                            Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. 
                            New England Journal of Medicine
                            , 381
                            (25)
                            , 2416-2428.
                            https://doi.org/10.1056/nejmoa1911361
                        

Identifiers

DOI: 10.1056/nejmoa1911361